Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder

International Journal of Urology

Volumn 17, Issue 11, 2010, Pages 931-936

  Watanabe, Miho ^a   Yamanishi, Tomonori ^a   Honda, Mikihiko ^a   Sakakibara, Ryuji ^b   Uchiyama, Tomoyuki ^c   Yoshida, Ken Ichiro ^a  

^a Dokkyo Medical University   (United Kingdom)

^b TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Neurogenic bladder; Overactive bladder; Pharmacotherapy; Tolterodine; Urodynamics

Indexed keywords

TOLTERODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER CONTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CYSTOMETRY; DRUG EFFICACY; FEMALE; HUMAN; INTERMITTENT CATHETERIZATION; INTERNATIONAL CONSULTATION ON INCONTINENCE QUESTIONNAIRE; KING HEALTH QUESTIONNAIRE; MALE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; OVERACTIVE BLADDER SYMPTOM SCORE; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; PROSPECTIVE STUDIES; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77958524725     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02635.x     Document Type: Article

References (18)

1. Yamaguchi O, Honda K, Nomiya M et al. Defining overactive bladder as hypersensitivity. Neurourol. Urodyn. 2007; 16: 904-7.
2. Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 2006; 68: 318-23.
3. Klovning A, Avery K, Sandvik H, Hunskaar S. Comparison of two questionnaires for assessing the severity of urinary incontinence: ICIQ-UI SF versus the Incontinence Severity Index. Neurourol. Urodyn. 2009; 28: 411-15.
4. Gotoh M, Homma Y, Funahashi Y, Matsukawa Y, Kato M. Psychometric validation of the Japanese version of the International Consultation on Incontinence Questionnaire-Short Form. Int. J. Urol. 2009; 16: 303-6.
5. Uemura S, Homma Y. Reliability and validity of King's Health Questionnaire in patients with symptoms of overactive bladder with urge incontinence in Japan. Neurourol. Urodyn. 2004; 23: 94-100.
6. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J. Urol. 2001; 19: 299-306.
7. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007; 100: 987-1006.
8. Yamaguchi C, Sakakibara R, Uchiyama T et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol. Urodyn. 2007; 16: 807-13.
9. Stöhrer M, Mürtz G, Kramer G et al. Propiverine Investigator Group: propiverine compared to oxybutynin in neurogenic detrusor overactivity: results of a randomized, double-blind, multicenter clinical study. Eur. Urol. 2007; 51: 235-42.
10. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J. Urol. 2009; 182: 1062-7.
11. Feifer A, Corcos J. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol. Urodyn. 2008; 27: 475-9.
12. Razdan S, Leboeuf L, Meinbach DS, Weinstein D, Gousse AE. Current practice patterns in the urologic surveillance and management of patients with spinal cord injury. Urology 2003; 61: 893-6.
13. Christoph F, Moschkowitsch A, Kempkensteffen C, Schostak M, Miller K, Schrader M. Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. Urol. Int. 2007; 79: 55-9.
14. Yamanishi T, Masuda A, Mizuno T et al. Ambulatory urodynamics in asymptomatic, young, healthy male volunteers. LUTS 2009; 1: 29-34.
15. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence society. Neurourol. Urodyn. 2002; 21: 167-78.
16. Harding C, Dorkin TJ, Thorpe AC. Is low bladder compliance predictive of detrusor overactivity? Neurourol. Urodyn. 2009; 28: 74-7.
17. Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K. Urodynamic effects of silodosin, a new α1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol. Urodynam. 2010; 29: 558-62.
18. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol. Urodyn. 2006; 25: 441-5.